BRIEF-Tarsus Pharmaceuticals Q2 EPS USD -0.43
Reuters2026/08/06 11:04Aug 06 (Reuters) - Tarsus Pharmaceuticals Q2 operating expenses USD 193.82 million.
- Q2 net income USD -18.551 million
- Q2 product sales USD 173.912 million vs. IBES estimate USD 169.7 million
- Q2 basic EPS USD -0.43
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fastenal August net sales rise 16.6% to $812.06 million
European cyclical stocks may see a rebound! Citi makes a major statement: The worst may be over, autumn is the perfect time to invest
Beata Manthey, Head of European Equity Strategy at Citigroup, stated that after a challenging period, European cyclical stocks—which are closely related to the health of the economy—now offer a rather attractive entry point.
Goldman Sachs cuts ADTRAN stake to 3.9% from 5.95% voting rights disclosure shows
British Pound pulls back from session highs as BoE Bailey tames rate hike hopes
Crypto prices
More
